Viewing Study NCT03302728

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 11:14 AM
Ignite Modification Date: 2026-06-08 @ 4:02 PM
Study NCT ID: NCT03302728
Status: COMPLETED
Last Update Posted: 2022-05-19
First Post: 2017-10-01
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Sponsor: Peter MacCallum Cancer Centre, Australia
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma, T-Cell, Cutaneous View
None Lymphoma, T-Cell, Peripheral View
None Hodgkin Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CD 30 positive, relapsed, refractory View